Evaluation of Osteocalcin and Pro-CoIlagen Type 1 Pro-Peptide as Predictors of Bone Integrity in Patients with Chronic Kidney Disease
DOI:
https://doi.org/10.17720/wed7na58Keywords:
CKD, bone disease osteocalcin and pro-collagen type 1 propeptideAbstract
The risk of fractures progressively increased with kidney function declines and in end-stage the kidney disease regarded as the risk of fractures is more 2 to 3 times higher compared to the general population. The gold standard for assessment of bone turnover is the measurement of bone formation rate in an iliac crest bone biopsy specimen. This is limited by expense, invasiveness and availability of local expertise. Plasma bone turnover markers were developed in osteoporosis patients for fracture risk prediction and assessment of medication compliance and anti-fracture efficacy. Therefore, the present study was aimed to evaluation the chemical biomarkers of bone integrity and to assessment the efficacy of these biomarkers as diagnostic and predictors biomarkers for early detection of complications of bone diseases in patients with chronic kidney disease. Methods. A case control study, involved 129 patient and 55 participants as control group. Cobas E311, C311 automated analyzer and ELISA technique were used to analysis the parameters. Results: The current study showed significant differences in the BMI (26.8), uric acid (4.34), urea (28.18), creatinine (0.76), phosphorus (3.42), calcium (9.12), vitamin D (31.55), albumin (4.30), alkaline phosphatase (74.49), bone specific alkaline phosphatase (1.83), parathyroid hormone (33.51), osteocalcin (1.84), pro-collagen typel propeptide and estimated GFR (88.15) in
control in comparison with BMI (24.1), uric acid (6.53), urea (139.4), creatinine (7.69),
phosphorus (6.309), calcium (8.813), vitamin D (15.14), albumin (3.79), alkaline phosphatase (120.2), bone specific alkaline phosphatase (11.85), parathyroid hormone (153.7), osteocalcin (9.392), pro-collagen typel propeptide (3.08) and estimated GFR (19.47) in patient, respectively. In the present study were no significant differences between CKD patients and healthy control, regarding to age (P =0.07) and gender (P =0.629). There were highly significant increases of urea, creatinine, uric acid, osteocalcin, pro-collagen type propeptide and estimated GFR, parathyroid hormone, Phosphorous, ALP levels; whereas showed significant decreases of vitamin D, albumin, calcium levels compared to the control group. Conclusion: There were significant decreases in each of vitamin D in patient with CKD; While, there were significant increases in each of ferritin, bone alkaline phosphatase, osteocalcin, and pro-collagen typel propeptide. They were good noninvasive biomarkers for prediction of bone turnover, risk stratification and assessment disease severity in CKD patients
Downloads
References
Ali, Salwa Abdalmoneim Mohammed. 2022.
Determination of Anti-Nuclear Antibodies,
Double Stranded DNA Antibodies and Renal
Functions in Patients with Dengue Fever, Red
Sea State, Sudan (2018-2021).
Ammirati, Adriano Luiz. 2020. “Chronic
Kidney Disease. Revista Da Associaqao Medica
Brasileira 66:s03—9.
Brown, J. P. et al. (2022) ‘Current use of
bone turnover markers in the management
of osteoporosis’, Clinical Biochemistry
Dalle Carbonare, L. etal. (2021) ‘Bone Biopsy
for Histomorphometry in Chronic Kidney
Disease (CKD): State-of-the-Art and New
Perspectives’, Journal of Clinical Medicine,
(19), p. 4617.
Pimentel, A. et al. (2017) ‘Fractures in
patients with CKD—diagnosis, treatment,
and prevention: a review by members of the
European Calcified Tissue Society and the
European Renal Association of Nephrology
Dialysis and Transplantation’, Kidney
international, 92(6), pp. 1343—1355.
Charles, Cornelia, and Allison H. Ferris. 2020.
“Chronic Kidney Disease. Primary Care: Clinicsin
Office Practice 47(4):585—95.
Chi, P.-J. et al. (2022) ‘Serum osteocalcin
concentration as an independent biomarker of
osteoporosis in patients with chronic kidney
disease.’, Clinical Nephrology.
Cohen-Solal, M., Funck-Brentano, T. and
Torres, P. U. (2020) ‘Bone fragility inpatients
with chronic kidney disease’, Endocrine
Connections, 9(4), p. R93.
Hafez, Eman Ahmed, Sameh Abd El-mottleb
Hassan, Mohammed Abdel Monem Teama,
and Fatma Mohammed Badr. 2021. Serum
Uric Acid as a Predictor for Nephritis in
Egyptian Patients with Systemic Lupus
Erythematosus. Lupus 30(3):378—84.
James, Armachius, Hengming Ke, Ting Yao,
and Yousheng Wang. 2021. “The Role of
Probiotics in Purine Metabolism,
Hyperuricemia and Gout: Mechanisms and
Interventions. Food Reviews International 1—
ll. Janousek, Ji i, Veronika Pila ova,
Kate ina Macakova, Anderson Nomura,
Jessica Veiga-Matos, Diana Dias da Silva,
Fernando Remiao, Luciano Saso,
Kate ina Mala-Ladova, and Josef Maly.
Vitamin D: Sources, Physiological
Role, Biokinetics, Deficiency,
Therapeutic Use, Toxicity, and Overview
of Analytical Methods for Detection of
Vitamin D and Its Metabolites. Critical
Reviews in Clinical Laboratory Sciences
(8):517-54.
Jorgensen, H. S. et al. (2022) ‘Diagnostic
accuracy of noninvasive bone turnover
markers in renal osteodystrophy’, American
Journal of Kidney Diseases, 79(5), pp. 667—
Jiang, Chongfei, Binyan Wang, Youbao Li,
Liling Xie, Xianglin Zhang, Jiancheng Wang,
Yaren Yu, Yun Song, Min Liang, and Guobao
Wang. 2020. U-Shaped Association between
Serum Albumin and Development of Chronic
Kidney Disease in General Hypertensive
Patients. Clinical Nutrition 39(1):258—64.
Kameda, Tomohito, Kazuya Horikoshi,
Shogo Kumagai, Yuko Saito, and ToshiakiYoshioka. 2020. “Adsorption of Urea,
Creatinine, and Uric Acid onto Spherical
Activated Carbon. Separation and
Purification Technology 237:116367.
Kalia, R. B., Ansari, S. and Regmi, A. (2022)
‘The interpretation of biochemical
investigations in the management of
metabolic bone disorders’, Journal of Cardio¬
diabetes and metabolic disorders, 2(1), p. 1.
Kawarazaki, Hiroo, Yugo Shibagaki, Seiji
Fukumoto, Ryo Kido, Katsuyuki Ando, Ichiro
Nakajima, Shohei Fuchinoue, Toshiro Fujita,
Masafumi Fukagawa, and Satoshi Teraoka. 2011.
“Natural History of Mineral and Bone Disorders
After Living Donor Kidney Transplantation: A
One Year Prospective Observational Study.
Therapeutic Apheresis and Dialysis 15(5):481—87.
Keronen, S. et al. (2019) ‘Changes in bone
histomorphometry after kidney
transplantation’, Clinical journal of the
American Society of Nephrology: CJASN,
(6), p. 894.
Kratz, M. et al. (2021) ‘Relationship between
chronic kidney disease, glucose homeostasis,
and plasma osteocalcin carboxylation and
fragmentation’, Journal of Renal Nutrition,
(3), pp. 248-256.
Koppe, Laetitia, Denis Fouque, and Kamyar
Kalantar Zadeh. 2019. Kidney Cachexia or
Protein energy Wasting in Chronic Kidney
Disease: Facts and Numbers. Journal of
Cachexia, Sarcopenia and Muscle 10(3):479—
Luft, Friedrich C. 2021. Biomarkers and
Predicting Acute Kidney Injury. Acta
Physiologica 231(1):el3479.
Marchelek-Mysliwiec, M. et al. (2018)
‘Association between plasma concentration of
klotho protein, osteocalcin, leptin,
adiponectin, and bone mineral density in
patients with chronic kidney disease’,
Hormone and Metabolic Research, 50(11), pp.
-821.
Mohamed, Shakir Hameed, Ahmed Methab
Athab, Nabeel Khalid mohammed Ali, and
Ismail Ibrahim Latif. 2019. Mineral
Derangement and Bone Diseases in Uremic
Patients on Hemodialysis in Ibn-Sina
Hemodialysis Center/Diyala. Diyala Journal
of Medicine 17(l):60—76.
Di Medio, L. and Brandi, M. L. (2021)
‘Advances in bone turnover markers’, in
Advances in Clinical Chemistry. Elsevier,
pp. 101-140.
Nonso, C. A., C. I. Sam, B. A. Ejikeme, A. Aliyu,
and D. O. Ifeyinwa. 2019. Responses of Urea,
Creatinine and Uric Acid to Soft Tissue and
Passive Mobilization in Patients with Renal
Diseases Undergoing Haemodialysis. J Nephrol
/er9(326):959—2161.
Novel-Catin, E. et al. (2020) ‘Quantitative
histomorphometric analysis of halved iliac
crest bone biopsies yield comparable ROD
diagnosis as full 7.5 mm wide samples’, Bone,
, p. 115460
Nizet, A. et al. (2020) ‘Bone alkaline
phosphatase: An important biomarker in
chronic kidney disease—mineral and bone
disorder’, Clinica Chimica Acta, 501, pp. 198—
Staykova, Sv, Ya Bocheva, and K. Prodanova.
Comparison of Specific Bone
Biomarkers in Chronic Kidney Disease
Bulgarian Patients with Secondary
Hyperparathyroidism. IOSR J. Dental Med.
Sci 17:85-90.
Tabata, Fuka, Yasuaki Wada, Satomi
Kawakami, and Kazuhiro Miyaji. 2021.
“Serum Albumin Redox States: More than
Oxidative Stress Biomarker. Antioxidants
(4):503.
Tentori, F. et al. (2014) ‘High rates of death
and hospitalization follow bone fracture
among hemodialysis patients’, Kidney
international, 85(1), pp. 166—173.
Tridimas, A., Milan, A. and Marks, E(2021) ‘Assessing bone formation in
patients with chronic kidney disease using
procollagen type I N-terminal propeptide
(PINP): The choice of assay makes a
difference’, Annals of Clinical Biochemistry,
(5), pp. 528-536.
Thanakun, S. et al. (2019) ‘Correlation of
plasma osteopontin and osteocalcin with
lower renal function in dental patients with
carotid artery calcification and tooth loss’,
Journal of Oral Biosciences, 61(3), pp. 183—
Tsai, Chun-Chieh, Yao-Peng Hsieh, Shr-Mei
Tsai, Chew-Teng Kor, and Ping-Fang Chiu.
Superiority of Albumin—Globulin Ratio
over Albumin to Predict Mortality in Patients
Undergoing Peritoneal Dialysis. Scientific
Reports 10(1):19764.
Wally, Riyadh Hussein. 2016. Effects of
Chronic Kidney Disease on Some Liver
Enzymes Activity Before and After Dialysis.
Journal of the College of Basic Education
(96):89—94.
Zabihi, Forough, Mohammad Amin Abbasi, and
Raheleh Alimoradzadeh. 2021. The Association
of Serum Albumin Level with Cognition and
Daily Function in Patients Undergoing
Hemodialysis. Annals of the Romanian Society for
Cell Biology 2573-79.
al Chemistry. Elsevier, pp. 101—140.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
